Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi to Snap Up UMN Pharma to Bolster Vaccine Biz
October 31, 2019
- Shionogi’s Half-Year Sales Slip 4.4% after Xofluza Milestone Gain
October 31, 2019
- Mitsubishi Tanabe to Give Another Try for Radicava’s EU OK, but in Oral Form: Chief
October 31, 2019
- Mitsubishi Tanabe Suffers 10% Sales Slide in 1st Half on Gilenya Royalty Row
October 31, 2019
- Taiwan Expands Hemlibra Label into Non-VIII Inhibitor Carriers
October 31, 2019
- Eisai Sees Brisk Sales of Global Brands, but Earnings Slump on One-Off Factors
October 31, 2019
- Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
- Taisho’s Prescription Drug Sales Suffer Double-Digit Decline in H1, due to Capital Tie-Up Dissolution with Toyama Chemical
October 31, 2019
- Taisho, Novartis to Stop Comarketing Lusefi at December-End
October 31, 2019
- Roche Going Beyond Oncology to Rev Up Precision Medicine Drive in Ophthalmology, Neuroscience
October 30, 2019
- AstraZeneca’s Japan R&D Chief Tapped as Medical Affairs SVP for Global Oncology Biz
October 30, 2019
- Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
- Nichi-Iko to Succeed 2 Off-Patent Brands from Astellas
October 30, 2019
- Debiopharm on Hunt for Japanese Ally for 1st-in-Class Cancer Drug, Eyes PIII Launch in 2020
October 29, 2019
- To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
- Desalex Resupply Scheduled from Nov. 18: Kyorin
October 29, 2019
- Astellas’ Kidney Injury Med Gets FDA’s Fast Track Status
October 29, 2019
- AbbVie Embarking on Work Style Reform for Sales Reps, Lets Staffers Pick Locations
October 28, 2019
- With European OK, Astellas’ Xospata Extends Lead over Daiichi Sankyo’s FLT3 Rival
October 28, 2019
- Mitsubishi Tanabe Ups H1 Earnings Forecast
October 28, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…